---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-070838"
form_type: "8-K"
ticker: null
cik: "0001567514"
company_name: "Intra-Cellular Therapies, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:21:42.384748+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intra-Cellular Therapies promotes Michael Halstead to President; CFO Hineline to retire

## Summary
- Michael Halstead, former EVP & General Counsel, promoted to President effective March 19, 2024.
- Halstead's base salary increased to $636,540; receives 36,717 time-based RSUs and 12,240 performance-based RSUs.
- CFO Lawrence Hineline intends to retire after 20+ years; company has initiated external search for successor.
- Hineline will remain through transition; departure not due to any disagreement.

## SEC filing metadata
- accession: 0001193125-24-070838
- form_type: 8-K
- cik: 0001567514
- company_name: Intra-Cellular Therapies, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/0001193125-24-070838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/d800974d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-070838
- JSON: https://secwatch.observer/filing/0001193125-24-070838.json
- Plain text: https://secwatch.observer/filing/0001193125-24-070838.txt

## Key facts
- Executive change
  Michael I. Halstead was appointed as President at Intra-Cellular Therapies, Inc..
  - Action: promoted
  - Role: President
  source text: On March 19, 2024, Intra-Cellular Therapies, Inc. (the “Company”) announced that the Company promoted Michael I. Halstead, the Company’s Executive Vice President, General Counsel and Secretary, to the role of President, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/0001193125-24-070838-index.htm
- Executive change
  Lawrence J. Hineline departed as Chief Financial Officer at Intra-Cellular Therapies, Inc..
  - Action: intends to retire
  - Role: Chief Financial Officer
  source text: On March 14, 2024, Lawrence J. Hineline notified the Company that he intends to retire as Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary of the Company following the appointment of his successor as Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/0001193125-24-070838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.